Rimantadine in Parkinson's disease patients experiencing peripheral adverse effects from amantadine: Report of a case series

Carlos Singer, Spiridon Papapetropoulos, Manuel A. Gonzalez, Eugene L. Roberts, Abraham Lieberman

Research output: Contribution to journalArticle

27 Scopus citations

Abstract

We report our experience with 7 consecutive patients with Parkinson's disease (PD) who received rimantadine (the α-methyl derivative of amantadine) in substitution of amantadine due to peripheral side effects (lower limb edema, livedo reticularis). Mean age was 67.3 ± 5.9 years, the mean disease duration was 13 ± 6.3 years, and mean Hoehn and Yahr stage was 2.2 ± 0.4. A total of 3 patients experienced marked improvement of edema, and 1 patient experienced marked improvement of livedo reticularis. Only 1 of the 7 patients reported significant loss of motor benefit when amantadine was replaced with rimantadine. Our results demonstrate that rimantadine may be considered as an alternative to amantadine in patients experiencing amantadine-induced peripheral side effects.

Original languageEnglish (US)
Pages (from-to)873-877
Number of pages5
JournalMovement Disorders
Volume20
Issue number7
DOIs
StatePublished - Jul 1 2005

Keywords

  • Amantadine
  • Edema
  • Parkinson's disease
  • Rimantadine

ASJC Scopus subject areas

  • Clinical Neurology
  • Neuroscience(all)

Fingerprint Dive into the research topics of 'Rimantadine in Parkinson's disease patients experiencing peripheral adverse effects from amantadine: Report of a case series'. Together they form a unique fingerprint.

  • Cite this